SCHEMBL433799

SCHEMBL433799

Cc1cccc2c1NC(=O)C2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.61
GRIA1 P42261 3/20 0.50
CACNG8 Q8WXS5 3/20 0.50
PDK2 Q15119 1/20 0.48
HTR5A P47898 1/20 0.47
TDP2 O95551 2/20 0.46
CASP3 P42574 1/20 0.46
CASP7 P55210 1/20 0.46
CASP9 P55211 1/20 0.46
CASP6 P55212 1/20 0.46
CASP8 Q14790 1/20 0.46
MAP3K14 Q99558 1/20 0.46
DAO P14920 1/20 0.44
CREBBP Q92793 2/20 0.44
MAPT P10636 1/20 0.42
CACNG2 Q9Y698 1/20 0.42
SMYD3 Q9H7B4 2/20 0.41
GRM5 P41594 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434004 0.82 NPC1 (0.50) AHRGRIA1CACNG8HTR5ADAO
Hydrochloric Acid SCHEMBL29961795 0.81 NPC1 (0.48) AHRGRIA1CACNG8HTR5ADAO
SCHEMBL31117301 0.79 MAPT (0.53) AHRGRIA1CACNG8HTR5ADAO
SCHEMBL10711685 0.79 AHR (0.47) AHRGRIA1CACNG8PDK2HTR5A
SCHEMBL31734657 0.78 CREBBP (0.58) AHRGRIA1CACNG8PDK2DAO
SCHEMBL18189620 0.78 GRIA1 (0.64) AHRGRIA1CACNG8TDP2CREBBP
SCHEMBL10953684 0.78 SMYD3 (0.50) AHRGRIA1CACNG8PDK2TDP2
SCHEMBL20886849 0.77 TDP2 (0.64) AHRGRIA1CACNG8PDK2TDP2
SCHEMBL12462776 0.77 AHR (0.58) AHRGRIA1CACNG8PDK2TDP2
SCHEMBL14555362 0.76 AHR (0.47) AHRGRIA1CACNG8PDK2TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3901153-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2021-10-27 EP claimed
US-20210284641-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-16 US claimed
EP-3288940-B9 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 EP claimed
EP-3288940-B1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 EP claimed
US-20180118740-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 US claimed
CN-107835814-A Azabenzimidazoles and their use as ampa receptor modulators 詹森药业有限公司 2018-03-23 CN claimed
EP-3288940-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 EP claimed
WO-2016176460-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 WO claimed
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 US disclosed
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators RAPPORT THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
WO-2025085819-A1 KINASE INHIBITOR COMPOSITIONS AND RELATED METHODS FOR THE TREATMENT OF A DISEASE WASHINGTON UNIVERSITY (US) 2025-04-24 WO disclosed
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-19 US disclosed
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-12 US disclosed
CN-111587239-B Method for producing lactam compound and lactam compound produced by the method 基础科学研究院 2024-04-02 CN disclosed
EP-0208510-A2 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents PFIZER INC. (US) 1987-01-14 EP disclosed
CN-86105309-A Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne 1987-01-14 CN disclosed
US-RE29882-E SALT FORMATION, REARRANGEMENT, DESULFURIZATION OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1979-01-16 US disclosed
US-4056569-A Ortho-[(alkylthio)(aminocarbonyl)methyl]anilines THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1977-11-01 US disclosed
US-3996264-A Synthesis of oxindoles from anilines and intermediates therein THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1976-12-07 US disclosed
US-3972894-A Synthesis of oxindoles from anilines and β-thio carboxylic esters or amides THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284641-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A AHR 2068/4885GRIA1 35/4885CACNG8 230/4885
US-20180118740-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A AHR 2068/4885GRIA1 35/4885CACNG8 230/4885
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A AHR 2068/4885GRIA1 35/4885CACNG8 230/4885
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A AHR 2068/4885GRIA1 35/4885CACNG8 230/4885
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A AHR 2068/4885GRIA1 35/4885CACNG8 230/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A AHR 2063/4885GRIA1 34/4885CACNG8 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.